Akebia Therapeutics (AKBA) Other Working Capital Changes (2013 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Other Working Capital Changes data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 238.55% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was -$2.3 million, a 55.15% increase from a year earlier, with the FY2025 full-year figure at -$5.4 million, down 20.22% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $1.8 million, up from -$5.7 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for AKBA reached as high as $8.7 million in Q4 2022 and fell as low as -$9.2 million in Q3 2022.
• Historically, Other Working Capital Changes has averaged -$1.7 million across 5 years, with a median of -$1.8 million in 2023.
• Across the five-year window, Other Working Capital Changes tumbled 2885.87% in 2024 and surged 349.07% in 2025, its largest moves.
• Year by year, Other Working Capital Changes stood at $506000.0 in 2022, then slumped by 1447.63% to -$6.8 million in 2023, then surged by 81.24% to -$1.3 million in 2024, then plunged by 341.91% to -$5.7 million in 2025, then surged by 132.11% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $1.8 million in Q1 2026, -$5.7 million in Q4 2025, and -$5.3 million in Q3 2025.